Aderbasib clinical trials
Also written INCB7839 and INCB007839.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How each study uses aderbasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2014 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Incyte Corporation (3) · Pediatric Brain Tumor Consortium (1) · Masonic Cancer Center, University of Minnesota (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses aderbasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- INCB7839 in Treating Children With Recurrent/Progressive High-Grade GliomasCompletedPhase 1Pediatric Brain Tumor ConsortiumNCT04295759Written as INCB7839
- ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCLCompletedPhase 1/2Masonic Cancer Center, University of MinnesotaNCT02141451Written as INCB7839
- Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast CancerTerminatedPhase 1/2Incyte CorporationNCT00864175Written as INCB007839
- Open-Label Study to Assess the Safety/Tolerability in Patients With Solid TumorsCompletedPhase 1Incyte CorporationNCT00820560Written as INCB007839
- Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast CancerTerminatedPhase 1/2Incyte CorporationNCT01254136Written as INCB007839 300mg BID
Codes
What other systems call aderbasib · ClinicalTrials.gg INT018227
- UNII (FDA) V9YL6NEJ3GADERBASIBConfirmed FDA, Wikidata
- Wikidata Q4682355aderbasibConfirmed FDA, Wikidata
- NCI Thesaurus C76115AderbasibOne source FDA
- DrugBank DB21288One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | V9YL6NEJ3G | ADERBASIB | Confirmed FDA, Wikidata |
| Wikidata | Q4682355 | aderbasib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C76115 | Aderbasib | One source FDA |
| DrugBank | DB21288 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.